



For immediate distribution  
Source: DIAGNOS inc.

**2011.04.06**

## **DIAGNOS Announces Representative in the Sultanate of Oman**

Brossard, Quebec, Canada – April 6<sup>th</sup>, 2011 - DIAGNOS inc. (“DIAGNOS” or “the Corporation”) (TSX Venture: ADK), a leader in the use of artificial intelligence and advanced knowledge-extraction techniques, announces today the signing of a distribution agreement with Gulf Health Solutions for the commercialization of CARA in The Sultanate of Oman. This signature was possible with the assistance of Canamexport with whom the company has now a strong alliance in international development.

Gulf Health Solutions is an Omani company based in Muscat and focuses on commercializing medical technologies in Oman and in other GCC countries. “We are pleased to be leveraging our network of relationships and working with DIAGNOS to bring CARA to clients in the Sultanate of Oman.” Said Mohammed Ahmed Al Malki, Gulf Health Solutions Founder and President.

“We are pleased to be working in collaboration with Gulf Health Solutions. We need local representation in different countries and we understand the importance of having local representatives. Our Omani prospects will now have access to a local Oman-based group of professionals to provide services and customer care. Understanding local culture and needs, is essential to sustain long term success in the Gulf Region,” said Peter Nowacki, DIAGNOS Vice-President, Healthcare.

### About CARA

CARA is a tele-ophthalmology platform that integrates with existing equipment (hardware and software) and processes at the point of care (POC) and comprises: image upload, image enhancement automated pre-screening, grading by a specialist, and referral to a specialist. CARA’s image enhancement algorithms make standard retinal images sharper, clearer, and easier to read. CARA is accessible securely over the internet, and is compatible with all recognized image formats and brands of fundus cameras. CARA is a cost-effective tool for processing large numbers of images, in real-time and has been issued a licence by Health Canada for commercialization in Canada.

### About CARA Field Trials

We have successfully conducted 20 field trials over the last 12 months in order to demonstrate CARA capability to target audiences and prospective clients, as well as to field test and refine our product and service offering. These trials were conducted in Canada, United States, Mexico, United Arab Emirates, Oman, and India, with future trials planned or scheduled for those countries as well as Kuwait, Bahrain, Qatar, Pakistan, Indonesia, China, Vietnam and others. The settings for these trials range from small regional health centres, to large (multi-million patient per year) hospital systems, as well as representatives of governments and health ministries. These trials form the basis for our robust sales pipeline and revenue forecast.

### About DIAGNOS

Founded in 1998, DIAGNOS is a publicly traded Canadian corporation with a mission to commercialize technologies combining contextual imaging and traditional data mining thereby improving decision making processes. DIAGNOS offers products, services, and solutions to clients in a variety of fields including natural resources, healthcare, and entertainment.



TSXV: ADK

*For immediate distribution*  
Source: DIAGNOS inc.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this press release.

For further information, please visit our website at [www.diagnos.com](http://www.diagnos.com) or the SEDAR website at [www.sedar.com](http://www.sedar.com). You may also contact our investor relations representative:

André Larente, President and CEO  
Telephone: 1-877-678-8882 or (450) 678-8882, ext.: 224

[alarente@diagnos.com](mailto:alarente@diagnos.com)